[Postoperative chemotherapy in non-small cell lung cancer].
Since 2000, seven prospective randomized studies were published or reported comparing surgery and surgery with post-operative chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Four trials (IALT, UFT, JBR10 and ANITA) are positive and have proved the benefit obtained with post-operative chemotherapy for the stages II and IIIA. For the stage IB, this survival increase is also probable, especially for the tumors higher than 4 cm. Several biologic markers are under investigation as predictors of the benefit of the chemotherapy.
Milleron
B
B
UF d'Oncologie Thoracique, Hôpital Tenon, Cancer Est, Paris, France. bernard.milleron@tnn.ap-hp.fr
Gounant
V
V
Giroux-Leprieur
Eacute
E
Lavolé
A
A
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011182:Postoperative Care